Dobutamine

别名: 多巴酚丁胺;丁巴多胺;酚乙丁胺;道必他安;盐酸多巴酚丁胺;4’-{2-[(3-对羟基苯基-1-甲基丙基)氨基]乙基}儿茶酚;外消旋多巴酚丁胺
目录号: V44704 纯度: ≥98%
多巴酚丁胺是一种合成儿茶酚胺,作用于肾上腺素能受体 α1-AR、β1-AR 和 β2-AR。
Dobutamine CAS号: 34368-04-2
产品类别: New3
产品仅用于科学研究,不针对患者销售
规格 价格
500mg
1g
Other Sizes

Other Forms of Dobutamine:

  • 盐酸多巴酚丁胺
  • 酒石酸多巴酚丁胺
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
产品描述
多巴酚丁胺是一种合成儿茶酚胺,作用于肾上腺素能受体 α1-AR、β1-AR 和 β2-AR。多巴酚丁胺是一种选择性β1-AR受体激动剂(激活剂),对α1-AR和β2-AR作用相对较弱。多巴酚丁胺可增加心输出量并纠正灌注不足。
生物活性&实验参考方法
体内研究 (In Vivo)
多巴酚丁胺起效快,半衰期短[2]。随着剂量的增加,多巴酚丁胺(0.15-20 mg/kg;腹腔注射)会导致野生型小鼠的左心室功能增强,心率增加[3]。高剂量的多巴酚丁胺在野生型小鼠中引起显着的正性肌力、舒张和变时性心脏反应[3]。低剂量多巴酚丁胺显着增强 Tgαq*44 动物的正性肌力和舒张心脏性能,而没有变时性改变 [3]。多巴酚丁胺仅在高剂量时才会增加心率,但随后会导致正性肌力和舒张心脏功能储备的丧失[3]。多巴酚丁胺通过激活 β-2 受体加速通气大鼠的肺泡液清除[4]。
动物实验
Animal/Disease Models: Tgαq*44 mouse (heart failure model) [3]
Doses: low dose 0.15mg/kg, 0.5mg/kg, high dose 1.5mg/kg, 5mg/kg, 20mg/kg: intraperitoneal (ip) injection
Experimental Results:Low Low and high doses produced differential responses in cardiac function in mice with heart failure.
药代性质 (ADME/PK)
Absorption, Distribution and Excretion
In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.
Biological Half-Life
2 minutes
毒性/毒理 (Toxicokinetics/TK)
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
No information is available on the use of dobutamine during breastfeeding. Because of its poor oral bioavailability and short half-life, any dobutamine in milk is unlikely to affect the infant.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information in nursing mothers was not found as of the revision date. Unlike dopamine, dobutamine infusion does not affect serum prolactin concentration in infants and in adult males. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
参考文献
[1]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36(1):185-96.
[2]. Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. Ann Cardiol Angeiol (Paris). 1991 Jun;40(6):397-402.
[3]. Tyrankiewicz U , et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. J Magn Reson Imaging. 2013 Mar;37(3):669-77.
[4]. Tibayan FA, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):438-44.
其他信息
Dobutamine is a catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure. It has a role as a cardiotonic drug, a sympathomimetic agent and a beta-adrenergic agonist. It is a secondary amine and a catecholamine.
A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Dobutamine is a beta-Adrenergic Agonist. The mechanism of action of dobutamine is as an Adrenergic beta-Agonist.
Dobutamine is a synthetic catecholamine with sympathomimetic activity. Dobutamine is a direct-acting inotropic agent and an adrenergic agonist that stimulates primarily the beta-1 adrenoceptor, with lesser effect on beta-2 or alpha receptors. Via beta-1 adrenoceptor of the heart, this agent induces positive inotropic effect with minimal changes in chronotropic activities or systemic vascular resistance. Dobutamine also causes vasodilation by stimulating beta-2 adrenergic receptors in blood vessels, augmented by reflex vasoconstriction resulting in increased cardiac output.
A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.
See also: Dobutamine Hydrochloride (has salt form); Dobutamine Tartrate (has salt form); Dobutamine Lactobionate (is active moiety of).
Drug Indication
Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
Treatment of neonatal circulatory failure
Mechanism of Action
Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.
Pharmacodynamics
Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with negligible effects on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine.
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C18H23NO3
精确质量
301.168
CAS号
34368-04-2
相关CAS号
Dobutamine hydrochloride;49745-95-1;Dobutamine tartrate;101626-66-8
PubChem CID
36811
外观&性状
Typically exists as solid at room temperature
密度
1.189g/cm3
沸点
527.7ºC at 760mmHg
熔点
184-186
闪点
169.8ºC
LogP
3.347
tPSA
72.72
氢键供体(HBD)数目
4
氢键受体(HBA)数目
4
可旋转键数目(RBC)
7
重原子数目
22
分子复杂度/Complexity
305
定义原子立体中心数目
0
SMILES
CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
InChi Key
JRWZLRBJNMZMFE-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
化学名
4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
溶解度 (体内实验)
注意: 如下所列的是一些常用的体内动物实验溶解配方,主要用于溶解难溶或不溶于水的产品(水溶度<1 mg/mL)。 建议您先取少量样品进行尝试,如该配方可行,再根据实验需求增加样品量。

注射用配方
(IP/IV/IM/SC等)
注射用配方1: DMSO : Tween 80: Saline = 10 : 5 : 85 (如: 100 μL DMSO 50 μL Tween 80 850 μL Saline)
*生理盐水/Saline的制备:将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中,得到澄清溶液。
注射用配方 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (如: 100 μL DMSO 400 μL PEG300 50 μL Tween 80 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如: 100 μL DMSO 900 μL Corn oil)
示例: 注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液,加到 900 μL Corn oil/玉米油中, 混合均匀。
View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如:100 μL DMSO 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备(4°C,储存1周):将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中,得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如: 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精) 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如: 50 μL DMSO 100 μL PEG300 200 μL Castor oil 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (如: 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如: 100 μL EtOH 900 μL Corn oil)
注射用配方 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (如: 100 μL EtOH 400 μL PEG300 50 μL Tween 80 450 μL Saline)


口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中,得到0.5%CMC-Na澄清溶液;然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中,得到悬浮液。
View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合


注意: 以上为较为常见方法,仅供参考, InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型,对于某些尚未有文献报道溶解方法的化合物,需通过前期实验来确定(建议先取少量样品进行尝试),包括产品的溶解情况、梯度设置、动物的耐受性等。

请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
CTID: NCT05350592
Phase: Phase 2    Status: Recruiting
Date: 2024-11-26
Dobutamine for Management of Surgical Patients With Septic Shock
CTID: NCT06462313
Phase: N/A    Status: Recruiting
Date: 2024-07-24
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
CTID: NCT05267886
Phase: Phase 4    Status: Recruiting
Date: 2024-04-08
Improving Tissue Oxygenation in Breast Reconstruction Surgery
CTID: NCT04020172
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-04-04
Novel Echocardiographic and Invasive Haemodynamic Measurements in the Assessment of Patients Low Flow Low Gradient Aortic Stenosis Undergoing TAVI
CTID: NCT05196815
Phase: N/A    Status: Completed
Date: 2024-03-26
View More

Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.
CTID: NCT05953142
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-01-30


Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
CTID: NCT04166331
Phase: Phase 3    Status: Recruiting
Date: 2023-12-12
Dobutamine Versus Milrinone in Management of Critically Ill Low Cardiac Output Pediatric Patients at Cairo University Children's Hospital
CTID: NCT05999487
Phase: N/A    Status: Not yet recruiting
Date: 2023-08-21
Consistency of Carotid Doppler Blood Flow and Thermodilution Technique
CTID: NCT05944146
Phase: N/A    Status: Recruiting
Date: 2023-07-13
Right Ventricular Contractile Reserve in HF
CTID: NCT05797584
Phase: N/A    Status: Recruiting
Date: 2023-04-04
Influence of Continuous Administration of Phenylephrine Versus Dobutamine on Spinal Oxygen Saturation, Measured With Near-infrared Spectroscopy (NIRS).
CTID: NCT03846765
Phase: Phase 4    Status: Completed
Date: 2022-12-12
Consistency of Electrical Cardiometry and Pulmonary Artery Catheter
CTID: NCT05587400
Phase: N/A    Status: Recruiting
Date: 2022-10-20
Supernormal Oxygen Delivery for Patients With Severe Burns
CTID: NCT05241912
PhaseEarly Phase 1    Status: Unknown status
Date: 2022-02-16
Dobutamine on the Cardiac Conduction System
CTID: NCT04249258
PhaseEarly Phase 1    Status: Completed
Date: 2022-01-26
Milrinone Versus Dobutamine in Critically Ill Patients
CTID: NCT03207165
Phase: Phase 4    Status: Completed
Date: 2020-06-30
Levosimendan Versus Dobutamine for Renal Function in Heart Failure
CTID: NCT02133105
Phase: Phase 3    Status: Completed
Date: 2020-02-25
Hemodynamics and Extravascular Lung Water in Acute Lung Injury
CTID: NCT00624650
Phase: Phase 2    Status: Completed
Date: 2019-09-10
Decision Support for Intraoperative Low Blood Pressure
CTID: NCT02726620
Phase: N/A    Status: Completed
Date: 2019-05-16
Effects of Intraoperative, Goal-directed Crystalloid vs. Colloid Fluid Resuscitation on Free Flaps
CTID: NCT03288051
Phase: N/A    Status: Completed
Date: 2019-05-15
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)
CTID: NCT01354613
Phase: N/A    Status: Completed
Date: 2019-04-11
Myocardial Regional Function by Dobutamine Stress Echocardiography in the Metabolic Syndrome and Type 2 Diabetes
CTID: NCT02505451
Phase: N/A    Status: Completed
Date: 2019-01-18
Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure
CTID: NCT02767024
Phase: Phase 4    Status: Withdrawn
Date: 2018-10-31
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
CTID: NCT00763035
PhaseEarly Phase 1    Status: Terminated
Date: 2018-09-26
Dobutamaine Versus Milrinone in Cardiorenal Syndrome
CTID: NCT02644057
Phase: Phase 2    Status: Withdrawn
Date: 2018-08-10
Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock
CTID: NCT02963454
Phase: N/A    Status: Unknown status
Date: 2018-02-12
Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period
CTID: NCT03311178
Phase: Phase 1/Phase 2    Status: Terminated
Date: 2017-10-17
NeoAdapt 3: Novel Biomarkers in the Evaluation of Neonatal Circulatory Insufficiency in Babies Suffering From Hypoxic Ischemic Encep
Norepinephrine alone vs Norepinephrine and Dobutamine in cardiogenic shock : a randomised, opened, cross-over study. Heart SHOCK-NORDOB Study
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2019-07-17
An international multicentre randomized placebo-controlled, double blind three arm trial to investigate the efficacy of dobutamine with two different starting doses in the treatment of haemodynamic insufficiency in the immediate postnatal period
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2018-07-24
Individualized perioperative hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS-trial)
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-08-04
A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery Disease
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-01-29
Evaluation of the effect of organic preservation with the use of levosimendan after cardiac surgery in patients with low output syndrom compared with dobutamine.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2015-01-19
Renal and cardiac effects of terlipressin and dobutamin in cirrhosis and ascites. A randomised study.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-01-15
An international multicentre open-label comparative therapeutic exploratory trial to investigate the role of a new neonatal formulation of dobutamine in the treatment of haemodynamic insufficiency in the immediate postnatal period
CTID: null
Phase: Phase 2    Status: Restarted, Completed
Date: 2013-12-03
Perioperative Goal Directed Fluid Therapy during Esophageal Resection. A prospective randomized controlled open multi-centre trial to study the effect on postoperative complications
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-10-11
Ensayo aleatorizado controlado sobre la terapia guiada por el antígeno carbohidrato 125 en los pacientes dados de alta por insuficiencia cardiaca aguda: efecto sobre la mortalidad a 1 año.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-08-02
Preoperative Optimization of the High-Risk Patient undergoing Hip Fracture Surgery
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-12-22
ESTUDIO ALEATORIZADO Y DOBLE CIEGO CON DOBUTAMINA VERSUS PLACEBO PARA EL TRATAMIENTO DEL BAJO FLUJO EN VENA CAVA SUPERIOR EN RECIÉN NACIDOS DE BAJO PESO: EVALUACIÓN SISTEMÁTICA DE LOS EFECTOS SOBRE LA HEMODINÁMICA CEREBRAL Y SISTÉMICA
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2010-04-14
TREATMENT OF HYPOTENSION IN EXTREMELY PRETERM INFANTS: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2010-04-13
An assessment of the effects of pressors on graft blood flow after free tissue transfer surgery: A randomised study – Part II
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2010-02-08
Comparaison du test au monoxyde d'azote aux épreuves pharmacologiques vasodiliatatrices et inotropes dans l'évaluation de la réversibilité de l'hypertension artérielle pulmonaire post-capillaire chez des patients candidats à la transplantation.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2009-01-19
Assessment of the effects of pressors on graft blood flow after free tissue transfer surgery
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-09-24
Cardiac imaging under dobutamine stress for early assessment of right ventricular function in patients with tetralogy of Fallot and pulmonary regurgitation
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2007-11-13
Etude des effets de l'enoximone sur la sensibilité du chémorécepteur.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-08-22
Prövning av hypotesen att lågdosinfusion av adenosin hos patienter med ischemisk hjärtsjukdom har en prekonditionerande effekt. En placebokontrollerad crossover-studie.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2006-05-22
Survival of patients with acute heart failure in need of intravenous inotropic support; a multicentre parallel- group, randomised, double- blind, double- dummy study of levosimendan versus dobutamine in patients with acute heart failure.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2004-10-28

相关产品
联系我们